Ultragenyx Pharmaceutical.
biopharmaceutical company based in Novato, California, United States
- Reports this week
- 4
- Active events
- 0
- Connections
- 63
What's happening
Earlier this month
-
Ultragenyx Pharmaceutical and Immunome, Inc. are being compared on various financial metrics, including share price volatility against the S&P 500.Some support1 report
-
Ultragenyx Pharmaceutical and Disc Medicine, Inc. are both mid-cap healthcare companies currently under review.Some support1 report
One to three months ago
-
Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.Some support9 reports
-
Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.Some support2 reports1 development inside
-
Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.Some support3 reports2 developments inside
-
Ultragenyx Pharmaceutical must file required documents regarding its NASDAQ company status with the SEC.Some support1 report
Gone quiet
No new reports in 90+ days-
Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.Some support1 report
-
Ultragenyx Pharmaceutical reported a grant under Nasdaq listing rules on June 21, 2025.Speculative1 report
-
The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.Well supported4 reports
-
The FDA rejected the biologics license application submitted by Ultragenyx Pharmaceutical.Some support3 reports
-
The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.Some support2 reports
-
Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.Some support1 report
-
The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.Some support1 report
-
William Blair maintained a bullish Buy stance on Ultragenyx Pharmaceutical on July 16, 2025.Some support1 report
-
FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.Some support2 reports
-
Ultragenyx Pharmaceutical and BioHarvest Sciences Inc. are companies operating in the Medical - Biomedical and Genetics industry.Well supported5 reports
-
Crysvita, a product of Ultragenyx Pharmaceutical, received breakthrough therapy designation for its drug GTX-102, while also generating revenue in Turkey and Europe.Well supported7 reports
-
Ultragenyx Pharmaceutical submitted a Rolling BLA for its DTX401 gene therapy to the FDA.Some support2 reports
-
Eric Crombez, who serves as Chief Medical Officer, was involved in a conference in London with Ultragenyx Pharmaceutical.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Ultragenyx Pharmaceutical this week
News at the entities that move Ultragenyx Pharmaceutical most-
Citigroup TransactionalCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Ultragenyx Pharmaceutical
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Ultragenyx Pharmaceutical
-
Cantor Fitzgerald TransactionalAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Ultragenyx Pharmaceutical
-
Jefferies Financial Group StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Ultragenyx Pharmaceutical
-
Royal Bank of Canada TransactionalRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves Ultragenyx Pharmaceutical
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves Ultragenyx Pharmaceutical
Connections
The 19 strongest of 63, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Citigroup Transactional
Citigroup raised its target price for Ultragenyx Pharmaceutical from $31.00 to $32.00, accompanied by a buy rating.
-
Emil Kakkis Structural
Emil Kakkis is the founder and chief executive officer of Ultragenyx Pharmaceutical.
-
FDA Structural
The FDA regulates Ultragenyx Pharmaceutical through drug approval processes, issuing designations and complete response letters.
-
Cantor Fitzgerald Transactional
Cantor Fitzgerald issues analyst reports and sets price targets for Ultragenyx Pharmaceutical.
-
Jefferies Financial Group Structural
Jefferies provides market ratings and price targets for Ultragenyx stock.
-
Royal Bank of Canada Transactional
Royal Bank of Canada issued a stock downgrade affecting market valuation of Ultragenyx Pharmaceutical.
-
Nasdaq Structural
Ultragenyx Pharmaceutical is a company that conducts its business and trades its stock on the Nasdaq exchange.
-
Eric Crombez Structural
Eric Crombez holds the formal position of Chief Medical Officer at Ultragenyx Pharmaceutical.
Show all 19 connections
-
ORBIT Structural
Ultragenyx's drug development progress depends on receiving study results from Orbit.
-
Morgan Stanley Mentioned together
Morgan Stanley provides investment ratings and price targets for Ultragenyx Pharmaceutical.
-
William P. Blair Mentioned together
William Blair, through its research firm, issued stock ratings for Ultragenyx Pharmaceutical, culminating in a downgrade.
-
Securities and Exchange Commission Structural
Ultragenyx Pharmaceutical must comply with SEC filing requirements for its company status.
-
North America Shared context
The company operates and generates revenue within the North American market region.
-
MarketBeat Mentioned together
MarketBeat publishes financial data, including average ratings and consensus price targets, for Ultragenyx Pharmaceutical.
-
TD Cowen Mentioned together
TD Cowen provides financial research coverage on Ultragenyx Pharmaceutical.
-
Turkey Shared context
Ultragenyx Pharmaceutical operates and generates revenue from its drug Crysvita within the market of Turkey.
-
Benzinga Mentioned together
Benzinga reports on company stock performance, including Ultragenyx Pharmaceutical's market activity.
-
Latin America Shared context
Ultragenyx Pharmaceutical is expanding its market presence within the Latin American region.
-
Novato Shared context
Ultragenyx Pharmaceutical is based in Novato, California.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
15 events- Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.
- Ultragenyx Pharmaceutical achieved compliance with Nasdaq Listing Rule 5635(c)(4) on August 22, 2025.
- Trump-era tariffs are noted to benefit certain AI stocks, while Ultragenyx and Mereo are involved in the ORBIT study.
- Ultragenyx Pharmaceutical reported a grant under Nasdaq listing rules on June 21, 2025.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- The FDA rejected the biologics license application submitted by Ultragenyx Pharmaceutical.
- The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.
- Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.
- The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
- William Blair maintained a bullish Buy stance on Ultragenyx Pharmaceutical on July 16, 2025.
- FDA issued a complete response letter for UX111, and Bank of America reiterated a Buy rating for Ultragenyx Pharmaceutical.
- Ultragenyx Pharmaceutical and BioHarvest Sciences Inc. are companies operating in the Medical - Biomedical and Genetics industry.
- Crysvita, a product of Ultragenyx Pharmaceutical, received breakthrough therapy designation for its drug GTX-102, while also generating revenue in Turkey and Europe.
- Ultragenyx Pharmaceutical submitted a Rolling BLA for its DTX401 gene therapy to the FDA.
- Eric Crombez, who serves as Chief Medical Officer, was involved in a conference in London with Ultragenyx Pharmaceutical.